Form 4: Sotera Health Exec's Routine Stock Transactions

Sotera Health's SVP, General Counsel, and Secretary, Alexander Dimitrief, reported vesting of restricted stock units and associated tax-related share dispositions.

Summary

• Alexander Dimitrief, SVP, General Counsel and Secretary of Sotera Health Co (SHC), reported several transactions on March 2, 2026.
• Received 16,816 shares of Common Stock from the vesting of performance-based Restricted Stock Units (RSUs) that were granted on March 3, 2025, based on the achievement of performance conditions.
• Disposed of 7,941 shares of Common Stock at a price of $15.91 per share to satisfy tax withholding obligations related to the vesting of 17,135 RSUs granted on March 4, 2024.
• Disposed of 23,619 shares of Common Stock at a price of $15.91 per share to satisfy tax withholding obligations related to the vesting of 50,448 RSUs granted on March 3, 2025.
• Following these reported transactions, Alexander Dimitrief directly beneficially owns 319,981 shares of Common Stock.
• An additional 11,210 performance-based RSUs remain outstanding, with future vesting scheduled for March 2027 and March 2028, subject to performance conditions.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a neutral event, reflecting standard executive compensation practices where RSUs vest upon meeting conditions, leading to both share acquisition and tax-related dispositions. The vesting of performance-based RSUs is a minor positive.

Positives

• The vesting of 16,816 performance-based RSUs indicates that specific performance conditions set by the company were met.

Negatives

• A total of 31,560 shares (7,941 + 23,619) were disposed of to cover tax withholding obligations, resulting in a reduction of direct beneficial ownership.

Future Outlook

Remaining 11,210 performance-based RSUs are scheduled to vest annually in equal installments in March 2027 and March 2028, contingent upon the achievement of specified performance conditions.

Industry Context

StockSavvy.ai notes that routine RSU vesting and associated tax-related sales are common for executives as part of their compensation packages. These transactions generally do not reflect a change in company fundamentals, strategic direction, or broader industry trends, but rather the execution of pre-established incentive plans.

Stakeholder Impact

• Shareholders: The vesting and subsequent tax-related sales are a routine part of executive compensation, aligning management interests with shareholder value creation through performance-based incentives. The impact on overall share count is minimal.
• Employees: These transactions reflect standard executive compensation practices under the 2020 Omnibus Incentive Plan, which can serve as a benchmark for other employee incentive programs.

Next Steps

• Vesting of remaining performance-based RSUs in March 2027, subject to performance.
• Vesting of remaining performance-based RSUs in March 2028, subject to performance.

Key Dates

Recommendation

This Form 4 details routine insider transactions related to the vesting of Restricted Stock Units (RSUs) and subsequent tax withholding sales. It does not introduce new material information regarding Sotera Health's financial performance, strategic direction, or operational outlook that would necessitate a change in investment recommendation. The transactions are an expected part of executive compensation and do not signal any fundamental shift in the company's prospects.

Keywords

Sotera Health, SHC, Alexander Dimitrief, Form 4, Insider Transaction, RSU Vesting, Executive Compensation, Stock Transactions